Jonathan Hall, MD, FACS to Be One of the First to Carry New Injectable DAXXIFY™

By on December 12, 2022 under Injectables

Jonathan Hall, MD, FACS to Be One of the First to Carry New Injectable DAXXIFY™

Stoneham, MA: Jonathan Hall, MD, FACS is proud to announce that he is one of the first providers to carry the new cosmetic injectable DAXXIFY™ at his practice. DAXXIFY™ is the first FDA-approved long-acting neuromodulator on the market. The active ingredient at the core of DAXXIFY™ is the same as BOTOX®: Botulinum Toxin A. However, unlike BOTOX®, DAXXIFY™ doesn’t contain human serum albumin or use animal products. When DAXXIFY™ was compared to BOTOX®, it has a stronger effect, faster onset, longer duration, and higher satisfaction rate in experienced patients with a comparable amount of core neurotoxin. DAXXIFY™ lasts on average six months and up to nine months in some patients.

DAXXIFY™ has undergone a multi-year study called the Sakura Study. The Sakura study is the largest and longest of its kind, treating patients up to three times and following out to 21 months. This study found that using the same amount of core neurotoxin as Botox, DAXXIFY™ has a median duration of six months, meaning that 1/2 of the patients had none or mild frown activity at six months. By comparison, Botox has an average duration of three to four months. DAXXIFY™ was also found to work more quickly than Botox, with an onset of one to two days.

“I am very excited to be able to be one of the first practices to be able to offer

my patients’ treatment with DAXXIFY™,” said Dr. Hall. “Revance has selected a few experienced injectors from around the U.S. to get initial access to DAXXIFY™ and flew us to Nashville so that we could learn the nuances of its use directly from the scientists involved in its development. Some of the doctors from the U.S. and Canada were part of the initial study.”

The safety profile in the Sakura Study is the same as with Botox. No serious adverse reactions were found in the study. The most common adverse reactions were headache and eyelid ptosis (drooping of an eyelid) after treatment.

“We are pleased to be one of the first practices to be able to offer this first-of-its-kind, long-lasting neuromodulator to our patients who want a longer-lasting neurotoxin,” said Dr. Hall. “We will still offer BOTOX® in the office for those patients who prefer a short-acting wrinkle treatment.”

Unlike many new products that start overseas or in Canada first, DAXXIFY™ is currently only available in the U.S.

About Jonathan D. Hall, MD, FACS: Dr. Hall is double board certified in Plastic Surgery as well as Facial Plastic surgery and has been delivering award-winning care in the Boston area for 30 years. He is honored to have been named a compassionate doctor by his patients for the past 10 years in a row. He has been a Castle Connolly Top Doctor as recognized by his peers since 2004. He has also had multiple mentions in Boston Magazine as a “Top Doc” and was recognized again in 2020. For more information about Dr. Hall and his practice, visit

Sign up for news & specials